Jefferies analyst Maury Raycroft maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating, and maintains the target price at $3.
According to TipRanks data, the analyst has a success rate of 37.4% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following an announcement that its partner will not pursue a Biologics License Application for an investigational gene therapy for treating hemophilia A, a significant asset has reverted back to Sangamo. The company expressed surprise at this turn of events. Despite this, the upside for alternative therapies such as those targeting Fabry disease remains considerable, even under restrained success probability estimations.
The unexpected return of Sangamo's hemophilia A program by a partner, notably close to the planned biologics license application, presents significant challenges. This shift disqualifies Sangamo from receiving $220 million in regulatory and first-sales milestones, thereby increasing its funding pressures. Although Sangamo's current cash reserves are anticipated to fund operations into the first quarter of 2025, the company is exploring partnerships for its Fabry gene therapy program to prolong its financial runway.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
